BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 08, 2007
 |  BioCentury  |  Finance

New products to watch

New products to watch

Company Product Indication 2006 approval
Alkermes (ALKS)/Cephalon (CEPH) Vivitrol injectable extended-release naltrexone Alcohol dependence U.S.
Amgen (AMGN) Vectibix panitumumab Metastatic colorectal cancer U.S.
Amylin (AMLN)/Eli Lilly (LLY) Byetta exenatide Type II diabetes where metformin and/or sulfonylurea not adequate; Type II diabetes where thiazolidi nedione (TZD) not adequate EU (metformin/sulfonylurea not adequate)/U.S. (TZD not adequate; already approved in U.S. where metformin/ sulfonylurea not adequate)
Avant (AVAN)/GlaxoSmithKline (LSE:GSK; GSK) Rotarix rotavirus vaccine Prevent gastroenteritis EU (already marketed in Mexico)
Axcan (TSX:AXP; AXCA) Pylera biskalcitrate/metronidazole/ tetracycline Helicobacter pylori infection U.S.
Barrier (BTRX) Vusion topical 0.25% miconazole Candida-associated diaper dermatitis U.S.
Barrier (BTRX) Xolegel...

Read the full 714 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >